Skip to main content

Advertisement

Table 1 Baseline characteristics of HIV-Infected, HCV-Infected, and HIV/HCV-coinfected patients (n = 59)

From: A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection

Variable Strata A (N = 15) Strata B (N = 15) Strata C (N = 14) Strata D (N = 15) P
Demographics      
Sex, N (%)      1.00
  Female 4 (27) 4 (27) 4 (29) 4 (27)  
  Male 11 (73) 11 (73) 10 (71) 11 (73)  
Age, years 53 (51–56) 54 (51–56) 54 (52–56) 53 (42–66) 0.95
Race/Ethnicity, N (%)      0.21
  African American/non-Hispanic 11 (73) 12 (80) 9 (64) 13 (87)  
  Caucasian/non-Hispanic 4 (27) 2 (13) 4 (29) 0  
  Caucasian/Hispanic 0 1 (7) 1 (7) 2 (13)  
Laboratory values      
ALT (U/L) 18(11–82) 43 (19–78) 23(14–88) 22 (10–77) 0.0009
AST (U/L) 19 (14–52) 37 (23–84) 30 (18–83) 24 (18–55) 0.0002
Albumin (g/dL) 4.2 (3.8-5.1) 4.0 (3.4-4.7) 4.3 (2.7-4.7) 4.2 (3.8-5.0) 0.29
Total cholesterol (mg/dL) 168 (118–253) 155 (88–200) 147.5 (98–207) 171 (124–220) 0.24
hs-CRP (mg/L) 4.0 (0.5-11.3) 1.2 (0.2-36.9) 0.7 (0.2-27.2) 3.5 (0.2-65.3) 0.08
D-dimer (μg/mL) 0.34 (0.19-0.98) 0.34 (0.21-2.25) 0.22 (0.19-2.07) 0.35 (0.19-1.49) 0.41
Risk factors, N (%)      
Sexual preference      0.01
  MSM 6 (40) 1 (7) 1 (7) 1 (7)  
  Heterosexual 7 (47) 14 (93) 11 (79) 14 (93)  
  Bisexual 2 (13) 0 2 (14) 0  
Alcohol use, N (%)      0.32
  > once a week 4 (27) 1 (7) 2 (14) 0  
  < weekly, but > monthly 2 (13) 1 (7) 2 (14) 1 (7)  
  Monthly or less 9 (60) 13 (86) 10 (72) 14 (93)  
Injection drug use ever, N (%)      <0.0001
  Yes 1 (7) 9 (60) 13 (93) 9 (60)  
  No 14 (93) 6 (40) 1 (7) 6 (40)  
TE-derived fibrosis score* 4.4 (3.0-11.6) 7.9 (4.7-29.9) 7.6 (3.2-22.3) 5.9 (3.0-9.1) 0.001
Current CD4 count (cells/μL) 495 (296–956) - 457 (299–651) 668 (295–1117) 0.01
Nadir CD4 count (cells/μL) 168 (22–415) - 225 (13–428) 302 (124–918) 0.08
Duration of ARVs (years) 9 (1–25) - 11(3–15) 6 (0–20) 0.59
Estimated duration of HIV (years) 12 (2–25) - 17 (5–31) 19 (1–28) 0.69
Estimated duration of HCV (years) - 24 (15–40) 30 (12–38) 26 (3–37) 0.23
HCV viral load (IU/mL) - 974,248 (1,622-4,604,960) 706,476 (17,145-20,000,000) - 0.95
  1. Values are expressed as median (range) unless otherwise noted. *TE-derived fibrosis scores correlate with Metavir fibrosis staging system as follows: <7.1 = stage 0–1, 7.1-9.4 = stage 2, 9.5-12.4 = stage 3, and ≥ 12.5 = stage 4.
  2. Strata: A = HIV monoinfection, B = HCV monoinfection, C = HIV/HCV coinfection with CHC, D = HIV/HCV coinfection with cleared HCV.
  3. Abbreviations: ARV, antiretroviral; hsCRP, high sensitivity C-reactive protein; MSM, men who have sex with men; TE, transient elastography.